20950-13-4

Basic information

• Product Name: 3-(4-nitrophenyl)-2-thioxo-1,3-thiazolidin-4-one
• Synonyms: 3-(4-nitrophenyl)-2-thioxo-1,3-thiazolidin-4-one
• CAS NO: 20950-13-4
• Molecular Weight: 254.29
• Mol File: 20950-13-4.mol
• Article Data: 4

Chemical Properties

• Melting Point: 232-234 °C
• Boiling Point: 432.5±47.0 °C(Predicted)
• Density: 1.63±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 3-(4-nitrophenyl)-2-thioxo-1,3-thiazolidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-nitrophenyl)-2-thioxo-1,3-thiazolidin-4-one(20950-13-4)
• EPA Substance Registry System: 3-(4-nitrophenyl)-2-thioxo-1,3-thiazolidin-4-one(20950-13-4)

Safety Data

• Hazardous Substances Data: 20950-13-4(Hazardous Substances Data)

Upstream product

• 68-11-1 mercaptoacetic acid 
• 2131-61-5 p-nitrophenyl isothiocyanate 
• 6326-83-6 bis(carboxymethyl)trithiocarbonate 
• 100-01-6 4-nitro-aniline 

Downstream Products

• 130189-23-0 5-Diethylaminomethyl-3-(4-nitro-phenyl)-2-thioxo-thiazolidin-4-one 
• 130189-43-4 3-(4-Nitro-phenyl)-5-piperidin-1-ylmethyl-2-thioxo-thiazolidin-4-one 

Relevant articles and documents

Design, synthesis and biological evaluation of 3-aryl-rhodanine benzoic acids as anti-apoptotic protein Bcl-2 inhibitors

A new class of 3-aryl-rhodanine benzoic acid derivatives were designed, synthesized, and evaluated for their inhibition activities against anti-apoptotic Bcl-2 proteins. The potent compounds 33 and 41 bound to Bcl-2 with submicromolar Ki values and had selectivities to Bcl-2/Mcl-1 over Bcl-xL. In addition, they exhibited obvious antiproliferative activities in three human tumor cell lines (MDA-MB-231, K562 and PC-3).

3. 5 - disubstituted the rhodanine class anti-withers apoptotic protein Bcl - 2 inhibitor and preparation method and application

The invention discloses a 3,5-disubstituted rhodanine anti-apoptosis protein Bc1-2 inhibitor as well as preparation method and an application thereof. The compound has a structure of a general formula I. The compound disclosed by the invention has high inhibitory activity on Bc1-2 and can be used for preparation of medicines for preventing or treating related mammal diseases caused by abnormal expression of anti-apoptosis protein Bc1-2. The invention also relates to a pharmaceutical application of a composition of the compound with the structure of the general formula I. The structural formula is as shown in the specification.